China said it will lift import restrictions on Illumina sequencers on Nov. 10, reopening a major market after months of trade frictions. Separately, Berry Genomics secured NMPA Class III approval for PacBio’s Sequel II CNDx sequencer paired with a thalassemia assay, a regulatory first for a clinical-grade long-read system in China. The moves signal renewed regulatory access for foreign and foreign-partnered sequencing platforms and could reshape competitive dynamics for genomics tools and clinical testing in China.